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Deletion of EP4 in S100a4-lineage 
cells reduces scar tissue formation 
during early but not later stages of 
tendon healing
Jessica E. Ackerman1, Katherine T. Best1, Regis J. O’Keefe2 & Alayna E. Loiselle  1
Tendon injuries heal via scar tissue rather than regeneration. This healing response forms adhesions 
between the flexor tendons in the hand and surrounding tissues, resulting in impaired range of motion 
and hand function. Mechanistically, inflammation has been strongly linked to adhesion formation, 
and Prostaglandin E2 (PGE2) is associated with both adhesion formation and tendinopathy. In the 
present study we tested the hypothesis that deletion of the PGE2 receptor EP4 in S100a4-lineage 
cells would decrease adhesion formation. S100a4-Cre; EP4flox/flox (EP4cKOS100a4) repairs healed with 
improved gliding function at day 14, followed by impaired gliding at day 28, relative to wild type. 
Interestingly, EP4cKOS100a4 resulted in only transient deletion of EP4, suggesting up-regulation of EP4 
in an alternative cell population in these mice. Loss of EP4 in Scleraxis-lineage cells did not alter gliding 
function, suggesting that Scx-lineage cells are not the predominant EP4 expressing population. In 
contrast, a dramatic increase in α-SMA+, EP4+ double-positive cells were observed in EP4cKOS100a4 
suggesting that EP4cKOS100a4 repairs heal with increased infiltration of EP4 expressing α-SMA 
myofibroblasts, identifying a potential mechanism of late up-regulation of EP4 and impaired gliding 
function in EP4cKOS100a4 tendon repairs.
Tendons are dense connective tissues composed primarily of a highly organized type I collagen extracellular 
matrix (ECM). The hierarchical structure of the collagen ECM allows tendons to transmit large forces between 
muscle and bone, facilitating movement of nearly the entire body. Acute traumatic injuries to the tendon are 
quite common due in part to the superficial anatomic location of many tendons. Following injury, tendons gen-
erally heal with a scar tissue response rather than regeneration of native tendon. This fibrotic healing response is 
particularly problematic in the hands, as excursion of the flexor tendons within the synovial sheath is restricted 
by both increased tissue bulk and the formation of adhesions between the tendon and surrounding tissues. 
Currently, treatment to restore digit range of motion (ROM) after injury is limited to surgical ‘tenolysis’ proce-
dures1, however this intervention provides only a temporary return to function. Thus, a better understanding of 
the fundamental cellular and molecular components of fibrotic healing are needed in order to inform develop-
ment of future therapeutic interventions to improve tendon healing.
Tendon healing is composed of three over-lapping phases of healing including inflammation, proliferative/ 
matrix deposition, and the remodeling phase. Several studies have demonstrated that anti-inflammatory treat-
ment, particularly Cox-2 inhibition, effectively reduces adhesion formation2, 3, however, mechanical properties 
can also be compromised with this approach2. Therefore, recent studies have focused on downstream signaling 
of Cox-2 as potential therapeutic targets. Cox-2 catalyzes the conversion of Arachidonic Acid to Prostaglandins, 
including PGE2, which is associated with tendinopathy and involved in tendon repair4–8. Moreover, EP4 has been 
identified as the specific receptor through which degenerative tendinopathic changes of PGE2 are mediated9. We 
have previously demonstrated that systemic EP4 antagonism increased adhesion formation, relative to vehicle 
treated repairs10, however the specific function of EP4 is dependent on cell type11, 12. Therefore, in the present 
study we have focused on the effects of cell-type specific EP4 deletion on tendon healing.
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In the present study we utilized S100a4-Cre; EP4flox/flox (EP4cKOS100a4) mice to test the hypothesis that condi-
tional deletion of EP4 in S100a4-lineage cells would reduce adhesion formation while maintaining mechanical 
properties, relative to wildtype (WT) littermates. S100a4 (S100 Calcium Binding Protein A4) is a member of the 
EF-hand Ca2+-binding proteins, and is associated with fibrosis in several tissues13–16. Given the fibrotic nature of 
scar-mediated tendon healing, we determined the feasibility of using S100a4-Cre as an efficient means to target 
the tendon during healing, and demonstrate recombination in both the un-injured tendon, and at the tendon 
repair site. We show that flexor tendon repairs from EP4cKOS100a4 have only a transient, early inhibition of EP4 
expression, concomitant with early reductions in adhesion formation. However, during later healing EP4 expres-
sion is increased in EP4cKOS100a4 repairs relative to WT, suggesting an alternative cell population up-regulates 
EP4 in these mice. We then show that loss of EP4 in Scleraxis-lineage cells does not alter adhesion formation, 
while EP4cKOS100a4 repairs have an increase in the myofibroblast marker α-SMA, suggesting a potential mecha-
nism of increased adhesion formation that occurs during later healing in EP4cKOS100a4 mice.
Results
S100a4-lineage cells are found in both native tendon and the granulation tissue. To determine 
the expression pattern of S100a4-lineage cells using S100a4-Cre, and thus the potential localization of EP4 con-
ditional deletion, the ROSAnT/nG dual reporter was used. GFP-expressing (S100a4-Cre+) cells were observed in 
40.5% of resident tenocytes in the absence of injury (Fig. 1A,D). At day 7 post-surgery abundant GFP+, S100a4-
Cre+ cells were observed throughout the native tendon and within the highly cellular bridging granulation tissue 
(Fig. 1B and B’, Supplemental Fig. 1), with 79.9% of cells in the scar tissue being nGFP+ (S100a4+) (p < 0.001 
vs. un-injured)(Fig. 1D). At day 14 post-repair a few GFP+, S100a4-Cre+ cells were observed in the ends of the 
native tendon, however, abundant GFP+, S100a4-Cre+ cells were present in the granulation tissue that bridges the 
injury site (Fig. 1C and C’), with 74.7% of cells in the scar tissue being nGFP+ (S100a4+) (p < 0.001 vs un-injured)
(Fig. 1D).
Figure 1. S100a4-Cre effectively targets tendon. To demonstrate that S100a4-Cre effectively targets 
recombination in the tendon we examined healing in the double reporter nT/nG with S100a4-Cre+ cells 
expressing GFP, and S100a4-Cre− cells expressing Td Tomato Red. S100a4-Cre results in recombination in both 
the (A) un-injured and (B & C) repaired tendon at days 7 (B & B’) and 14 (C & C’) post-surgery. Tendon tissue 
is outlined in white, (*) indicate auto-fluorescent sutures at the repair site. Scale bars (A,B’,C’) represent 100 
microns, and (B & C) 200 microns. (D) Quantification of the proportion of nGFP+ (S100a4-Cre+) cells in the 
un-injured tendon and at 7 and 14 days post-repair. (***) Indicates p < 0.001 vs. un-injured.
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EP4cKOS100a4 Does not alter mechanical properties of un-injured tendons. To ensure that 
EP4cKOS100a4 did not impair baseline mechanical properties and gliding function of the FDL, un-injured tendons 
were used. No change in Max load at failure (WT: 7.33 N ± 0.35; EP4cKOS100a4: 7.89 ± 0.67 p = 0.46) (Fig. 2A), 
stiffness or energy to Max (data not shown) were observed between un-injured EP4cKOS100a4 and WT tendons. 
Additionally, no change in MTP flexion angle (WT: 51.98 ± 1.75; EP4cKOS100a4: 51.78 ± 3.95, p = 0.96) (Fig. 2B) 
and Gliding Resistance (WT: 9.63 ± 0.95; EP4cKOS100a4: 11.09 ± 2.11, p = 0.53) were observed between genotypes 
(Fig. 2C).
EP4 expression is decreased during early but not late healing in EP4cKOS100a4 tendon 
repairs. To determine the temporal effects of EP4cKOS100a4 on EP4 expression during healing, mRNA was 
isolated from WT and EP4cKOS100a4 repairs between 7 and 28 days post-repair. Peak EP4 expression was observed 
in WT repairs at day 7 post-repair, consistent with previous studies10, followed by a significant reduction in EP4 
expression at 14, 21 and 28 days, relative to day 7. A significant 63.9% reduction in EP4 expression was observed 
in EP4cKOS100a4 repairs relative to WT (p = 0.0135, Fig. 3) at day 7, identifying efficient reduction in EP4 expres-
sion at this time. In contrast, EP4 expression was significantly increased in EP4cKOS100a4 repairs at days 14 and 
21, relative to time-point matched WT repairs. No change in EP4 expression was observed between WT and 
EP4cKOS100a4 repairs at day 28 (Fig. 3).
Figure 2. EP4cKOS100a4 does not alter gliding function or mechanical properties of un-injured tendons. No 
changes in (A) Max load at failure, (B) MTP Flexion Angle, or (C) Gliding Resistance were observed between 
un-injured tendons from WT and EP4cKOS100a4 flexor tendons. For tensile testing, all un-injured tendons failed 
at the tendon mid-substance.
Figure 3. EP4cKOS100a4 significantly decreases EP4 expression during early healing. mRNA was isolated from 
EP4cKOS100a4 and WT tendon repairs between 7–28 days post-surgery. Relative EP4 expression was significantly 
decreased in EP4cKOS100a4 relative to WT at day 7, and was significantly increased on days 14 and 21 post-
surgery. Expression was normalized to the internal control β-actin. (*) Indicates p < 0.05.
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EP4cKOS100a4 flexor tendon repairs have an early, transient improvement in gliding function. 
No differences in MTP flexion angle were observed at day 10 post-repair between WT and EP4cKOS100a4 mice. 
However, by day 14 a significant 71% increase in MTP Flexion angle was observed in EP4cKOS100a4 repairs 
(WT: 14.53 ± 1.74; EP4cKOS100a4: 28.55 ± 5.44, p = 0.03). At 21 days MTP flexion was not different between 
genotypes, however, at 28 days MTP Flexion was significantly increased in WT repairs relative to EP4cKOS100a4 
repairs (p = 0.03) (Fig. 4A). A significant increase in Gliding Resistance occurred in WT repairs at day 14, rela-
tive to EP4cKOS100a4 (WT: 65.00 ± 8.06; EP4cKOS100a4: 37.60 ± 7.887 p = 0.034) (Fig. 4B). No changes in Gliding 
Resistance were observed between groups at any other time-points.
EP4cKOS100a4 does not impair mechanical properties during flexor tendon healing. Max load at 
failure improved progressively in both WT and EP4cKOS100a4 repairs from day 14 to day 28. While no differences 
were observed in max load at failure between genotypes at a given time point, accrual of strength was slightly 
retarded in EP4cKOS100a4 repairs, and there was a trend toward decreased max load at failure in EP4cKOS100a4, 
relative to WT at Day 28 (p = 0.068). The max load at failure improved 328% in WT repairs from day 14 to Day 
28 (Day 14: 0.83 ± 0.09; Day 28: 3.57 ± 0.62). In contrast, EP4cKOS100a4 repairs regained only 176% of max load 
at failure from day 14 to day 28 (Day 14: 0.78 ± 0.14; Day 28: 2.164 ± 0.31) (Fig. 4C). No differences in stiffness 
occurred between WT and EP4cKOS100a4 repairs at any time, however, there was a trend toward an increase 
in stiffness in WT, relative to EP4cKOS100a4 at day 28 (WT: 0.739 ± 0.07; EP4cKOS100a4: 0.399 ± 0.16, p = 0.076)
(Fig. 4D).
EP4cKOS100a4 Repairs Heal with Decreased Expression of Col1a1 and Col3a1. No change in 
Col1a1 expression was observed between groups at day 7 post-surgery, and the typical progressive increase 
in Col1a1 was observed in WT repairs between 7–21 days, followed by a return to baseline levels by day 28. 
In contrast, Col1a1 was significantly decreased in EP4cKOS100a4 repairs at day 14 post-surgery relative to WT 
(WT: 7.3 ± 3.34; EP4cKOS100a4: 0.76 ± 0.22, p = 0.03), followed by a non-significant decrease at day 21 (WT: 
10.36 ± 5.11; EP4cKOS100a4: 5.20 ± 1.52, p = 0.1) (Fig. 5A). Additionally, Col3a1 increased transiently in WT 
repairs from day 7–14, followed by a gradual decline back to baseline levels by day 28. Col3a1 expression was sig-
nificantly decreased in EP4cKOS100a4 repairs at day 14 relative to WT (WT: 5.8 ± 1.27; EP4cKOS100a4: 1.37 ± 0.94, 
p = 0.04). No changes in Col3a1 expression were observed between groups at 21 or 28 days post-surgery (Fig. 5B). 
Figure 4. EP4cKOS100a4 significantly improves early gliding function without compromising mechanical 
properties during flexor tendon healing. (A) MTP Flexion Angle, and (B) Gliding Resistance were measured 
in WT and EP4cKOS100a4 flexor tendons between 10–28 days post-surgery. (C) Max load at failure, and (D) 
Stiffness were assessed between 14–28 days post-surgery. For tensile testing, all repaired tendons failed at the 
suture site. (*) Indicates p < 0.05 between WT and EPcKOS100a4 at the same time-point.
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These data resulted in an elevated Col1a1/Col3a1 ratio at 7 and 21 days post-surgery in WT repairs relative to 
EP4cKOS100a4.
Loss of EP4 in Scleraxis-lineage cells does not alter flexor tendon healing. The substantial 
increase in EP4 expression in EP4cKOS100a4 repairs suggests a cell population separate from S100a4-lineage 
expresses EP4 during the later stages of healing. As a potential alternative population of EP4 expressing cells, we 
examined the effects of EP4 deletion in Scleraxis-lineage cells.
Tracing of Scx-lineage cells labels almost all resident tenocytes in the un-injured flexor tendon (green cells, 
Fig. 6A). Following injury there is an expansion of the Scx-lineage cells, with localization in both the native 
tendon and reactive epitenon, with very few Scx-lineage cells in the bridging scar tissue (Fig. 6B, Supplemental 
Fig. 2).
At day 14 post-repair no change in MTP flexion angle was observed between WT and EP4cKOScx (p = 0.83, 
Fig. 6C). Consistent with this, no change in Gliding Resistance was observed between genotypes (Fig. 6D). 
Additionally, Max load at failure (WT: 1.48 N ± 0.4; EP4cKOScx: 0.97 N ± 0.15, p = 0.17) (Fig. 6E), and Stiffness 
(p = 0.75) (Fig. 6F) were not altered by conditional deletion of EP4 in Scx-lineage cells.
α-SMA myofibroblasts are increased in EP4cKOS100a4 repairs during later healing. Given that 
adhesion formation increases during later healing in EP4cKOS100a4 repairs we examined changes in pro-fibrotic, 
matrix producing myofibroblasts17 as a potential mechanism of increased scar formation. α-SMA expressing cells 
were observed in both the native tendon and scar tissue of WT repairs at day 21 (Fig. 7A, Supplemental Figs 3 
and 4), and no difference in α-SMA+ cell area was observed between WT and EP4cKOS100a4 repairs (Fig. 7C). 
However, abundant co-localization of α-SMA and EP4 were observed in EP4cKOS100a4 repairs at day 21 (yellow 
arrows, Fig. 7B, Supplemental Fig. 4), particularly in the scar tissue, with 9.5% of the cell area positive for both 
α-SMA and EP4 (Fig. 7E). In contrast, very few double positive (α-SMA+, EP4+) cells were observed in WT 
repairs (0.61%) (Fig. 7E), consistent with a decrease in EP4+ cells at this time-point in WT (4.5%) relative to 
EP4cKOS100a4 (29.8%, p = 0.0012) (Fig. 7D). No further expression of EP4 was observed in the native tendon 
beyond the area immediately adjacent to the repair site (Fig. 7B).
Discussion
In the present study we have examined the effects of deleting the PGE2 receptor, EP4, specifically in 
S100a4-lineage cells during flexor tendon healing. Given the strong association between inflammation and scar 
tissue formation18, we tested the hypothesis that loss of EP4 in S100a4-lineage cells would decrease adhesion for-
mation and improve tendon gliding function. Our data demonstrate that EP4cKOS100a4 improves tendon gliding 
at 14 days post-surgery, consistent with a significant decrease in EP4 expression prior to this point. Conversely, 
gliding function during the later stages of healing (day 28) is impaired, while EP4 expression is similarly increased 
prior to these functional deficits. Taken together, these data suggests that early deletion of EP4 in S100a4-lineage 
cells alters the kinetics of healing, potentially resulting in changes in the cellular milieu, and up-regulation of 
EP4 by an alternative cell population during later healing. To determine the effects of EP4 deletion in a different 
cell population, we examined healing in mice with EP4 deletion in Scleraxis-lineage cells and found no effect on 
gliding function or mechanical properties. We then examined α-SMA+ myofibroblasts as potential cell mediator 
of increased EP4 expression and adhesion formation during late healing in EP4cKOS100a4 mice. A substantial 
increase in α-SMA+, EP4+ double-positive cells were observed in EP4cKOS100a4, suggesting that an influx of 
EP4-expressing α-SMA+ myofibroblasts may drive the up-regulation of EP4, potentially re-activating inflam-
mation and promoting scar-mediated tendon healing.
Figure 5. EP4cKOS100a4 repairs heal with decreased expression of Col1a1 and Col3a1. mRNA was isolated from 
EP4cKOS100a4 and WT mice between 7–28 days post-surgery. A significant decrease in both (A) Col1a1, and 
(B) Col3a1 expression was observed at day 14 post-surgery in EP4cKOS100a4 relative to WT. Expression was 
normalized to the internal control β-actin. (*) Indicates p < 0.05.
www.nature.com/scientificreports/
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Immediately following tendon injury the acute inflammatory phase begins. While inflammation is necessary 
for the initiation and progression of the normal healing cascade, there is clear evidence that inflammation can also 
drive the scar tissue healing response in tendon. Embryonic19, 20 and early post-natal17 healing are characterized 
by scarless, regenerative healing in contrast to healing in mature tissues which tend toward a scar tissue response. 
Changes in the inflammatory and immune environment have been proposed as a main factor in this differential 
response as the embryonic and early post-natal environment has an altered immune system, relative to adult21, 22. 
Furthermore, MRL/MPJ mice, which have a blunted inflammatory response23, also demonstrate improved ten-
don healing24. Therefore, modulating inflammation represents a promising approach to improve tendon healing. 
Cox-2 inhibitors have shown promising inhibition of adhesion formation2, 3, however systemic Cox-2 inhibitors 
are plagued by side-effects, including increased risk of adverse cardiovascular events, that must be given serious 
consideration25, 26. Thus, we have focused on downstream targets of Cox-2 mediated inflammation, specifically 
the Prostaglandin E2 receptor, EP4. We have previously demonstrated that systemic antagonism of EP4 impaired 
gliding function during tendon healing. However, several studies have demonstrated the differential effects of 
Figure 6. EP4cKOScx does not alter tendon healing. (A,B) Tracing of Scx-lineage cells using Scx-Cre; nT/nG 
demonstrates that Scx-lineage cells are present in the un-injured tendon (A), and the repaired tendon at day 
14 post-surgery (B). Scale bar represents 100 microns. (C–F) Repaired tendons from EP4cKOScx and WT mice 
were harvested at day 14 post-surgery. No changes in (C) MTP Flexion Angle, (D) Gliding Resistance, (E) Max 
load at failure, (F) Stiffness were observed between WT repairs and EP4cKOScx repairs. For tensile testing, all 
repaired tendons failed at the suture site.
www.nature.com/scientificreports/
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EP4 in a cell-type dependent context. Yokoyama et al., demonstrated that pharmacological antagonism of EP4, 
or genetic knock-down of EP4 decreased abdominal aortic aneurysms27. However, Tang et al., demonstrate that 
bone marrow cell-specific deletion of EP4 promotes abdominal aortic aneurysms12. Taken together these data 
support investigating cell-type specific effects of EP4 deletion on tendon healing.
The differential effects of systemic versus cell-type specific EP4 inhibition are demonstrated by alterations 
in ECM gene expression. EP4 antagonist treatment resulted in earlier expression of Col3a1, relative to vehicle 
treated repairs10, suggesting that systemic EP4 antagonism promotes an accelerated shift toward scar-mediated 
healing. In contrast, Col3a1 was significantly decreased in EP4cKOS100a4 repairs, relative to WT repairs, consist-
ent with improved gliding in EP4cKOS100a4 repairs at that time-point. However, expression of Col1a1, which is 
associated with restoration of native tendon composition, is also decreased in EP4cKOS100a4 repairs throughout 
Figure 7. EP4-expressing α-SMA myofibroblasts are increased in EP4cKOS100a4 repairs during later healing. 
(A) Abundant expression of α-SMA+ was observed in EP4cKOS100a4 and WT repairs on day 21 post-
surgery. α-SMA+ cells are identified by red fluorescent staining, while nuclear stain DAPI is blue. Scale bars 
represent 200 microns. (B) Co-immunofluorescence for α-SMA (red) and EP4 (green) demonstrate very 
few α-SMA+, EP4+ cells (yellow arrow) in WT repairs at day 21. In contrast, abundant α-SMA+, EP4+ cells 
(yellow arrows) are observed in EP4cKOS100a4 repairs at this time. Scale bars represent 50 microns. (D–F) 
Quantitative assessment of (D) α-SMA+ cells, (E) EP4+ cells, and (F) α-SMA, EP4 double positive cells by 
immunofluorescence at day 21. (**) Indicates p < 0.01 between WT and EP4cKOS100a4 repairs.
www.nature.com/scientificreports/
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healing, suggesting that EP4cKOS100a4 disrupts the normal progression of tendon healing. Based on gliding func-
tion, mechanics and gene expression data, WT repairs progress through the normal phases of healing, with pro-
gressive acquisition of mechanical properties, a transient decrease in gliding function, and a shift from early 
Col3a1 expression to Col1a1. In contrast, no change in gliding function is observed over the course of healing in 
EP4cKOS100a4, and diminished acquisition of mechanical properties occurs; max load at failure increases 102% 
in WT repairs from day 21 to day 28, compared to a 1.6% increase in max load over the same time-period in 
EP4cKOS100a4 repairs. Indeed, following an early failure to form adhesions, EP4cKOS100a4 repairs seem to remain 
relatively static, as no change in GR or MTP Flexion angle is observed over time, and no up-regulation of Col3a1 
or Col1a1 is observed. Taken together, these data may suggest that early deletion of EP4 in S100a4-lineage cells 
halts progression through the normal phases of tendon healing.
Given the differences in healing between EP4 antagonist treated mice, and EP4cKOS100a4 mice, we examined 
the effects of EP4 conditional deletion in Scleraxis-lineage cells. Scleraxis is required for normal tendon forma-
tion28, and is expressed by resident tenocytes in mature tendon17. Recently, Scx-lineage cells have been shown 
to participate in regenerative tendon healing in neonates, with minimal involvement of Scx+ cells in mature, 
scar mediated healing17, which may account for the lack of phenotype observed in EP4cKOScx. Furthermore, 
while Scx-lineage cells are observed in the healing tendon (Fig. 6), we have used a non-inducible Scx-Cre, so it is 
unknown if these Scx-lineage+ cells are residual cells from development, or newly activated Scx-expressing cells 
that are involved in healing.
Myofibroblasts are believed to be the cellular drivers of fibrotic tendon healing and peritendinous adhesions29, 30, 
given their ability to produce abundant collagenous ECM. We have used α-SMA expression to identify myofi-
broblasts, consistent with many other studies31–33. However, α-SMA has also been used to mark mesenchymal 
progenitors34. While future studies will clarify the lineage, fate and function of these cells during tendon heal-
ing, there is a consistent demonstration of the involvement of α-SMA+ cells during tendon healing. While our 
data suggest that α-SMA+ myofibroblasts drive the up-regulation of EP4 that occurs during later healing in 
EP4cKOS100a4, it is not clear if the increase is driven by elevated levels of the EP4 ligand PGE2, and which cells 
are producing PGE2 at this stage in healing. Macrophages play important roles in both initiation and resolution 
of inflammation, and have been shown to produce PGE235. However, PGE2 can also alter macrophage polariza-
tion36, 37, and recent work by Fernando et al., demonstrate that myofibroblast-derived PGE2 can promote alterna-
tive activation of macrophages38. Thus, understanding the relationship between myofibroblasts, macrophages and 
PGE2/EP4 signaling during tendon healing will be an important area of future research.
While these data clearly identify different cell-type specific functions of EP4 in tendon healing there are sev-
eral limitations that must be considered. We have examined the effects of EP4cKOScx at only one time-point 
during healing, however, if EP4cKOScx were to alter healing, our previous data would suggest these effects would 
occur prior to day 14 based on the expression profile of Scx in this healing model39. We have also not examined 
the long-term mechanical effects of EP4cKOS100a4 on tendon healing. In addition, the actual identity of S100a4+ 
cells is both unclear and controversial. Osterreicher et al., have identified S100a4+ cells as a sub-population of 
inflammatory macrophages40, while Nishitani et al., identified S100a4+ cells as myofibroblasts41. Thus, future 
studies to more clearly define the origin, fate and function of S100a4 during tendon healing are needed. In addi-
tion, we have not examined the role of other EP receptors in EP4cKOS100a4 repairs, which will be an important 
consideration in future studies, given that loss of EP2 is associated with fibrotic progression in the lung ability 
of EP2 in particular to also promote fibrosis42, 43. While these data suggest a role for α-SMA+ cell-mediated EP4 
induction, and increased scar formation, conditional deletion studies of EP4 using an α-SMA-Cre mouse would 
be required to definitively identify the role of EP4 in α-SMA-lineage cells. Finally, the release of the FDL tendon 
at the proximal myotendinous junction (MTJ) decreases strain on the repair to protect the repair site, however, 
this is likely to alter healing. However, some restoration of the MTJ is observed during healing, although we have 
not measured this strain experimentally, and therefore do not know what the effects of this release or restoration 
of the MTJ are on healing.
Together with our previous studies using an EP4 systemic antagonist, these data demonstrate cell-type specific 
functions of EP4 in scar-mediated tendon healing. Our data suggest that deletion of EP4 in S100a4-lineage cells 
inhibits range of motion-limiting scar tissue without further compromising mechanical properties. However, 
these beneficial effects of EP4cKOS100a4 are transient, with aberrant up-regulation of EP4 during later healing, 
mediated at least in part by α-SMA+ cells, and a subsequent decrease in range of motion. These data suggest 
that sustained inhibition of EP4 in S100a4-lineage cells, and α-SMA-lineage cells may result in prolonged 
improvements in tendon healing. Furthermore, understanding the mechanisms through which EP4 promotes 
scar-mediated healing will identify novel therapeutic targets to improve tendon healing.
Methods
Animal Ethics. This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal procedures were 
approved by the University Committee on Animal Research (UCAR) at the University of Rochester (UCAR 
Number: 2014-004).
Mice. The following strains were obtained from Jackson Laboratories (Bar Harbor, ME): EP4flox/flox (#28102), 
ROSAnT/nG (# 23035) s100a4-Cre (#12641). The S100a4-Cre44 mice were generated on a BALB/cByJ background 
and were back-crossed to C56Bl/6 J for at least 10 generations prior to crossing to EP4flox/flox or ROSAnT/nG strains. 
Scx-Cre mice were generously provided by Dr. Ronen Schweitzer. Conditional knock-out animals were gener-
ated as homozygotes (Cre+; EP4flox/flox), Cre−; EP4flox/flox littermates were used as wildtype (WT). The ROSAnT/nG 
construct is a dual reporter in which all cells express nuclear Tomato red (nT) fluorescence in the absence of 
Cre-mediated recombination, and nuclear GFP (nG) upon Cre-mediated recombination.
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Flexor Tendon Surgery. At 10–12 weeks of age mice underwent complete transection and repair of the 
flexor digitorum longus (FDL) tendon in the right hind-paw as previously described39, 45. Briefly, mice were anes-
thetized with Ketamine (60 mg/kg) and Xylazine (4 mg/kg). A pre-surgical dose of Buprenorphine (0.05 mg/kg) 
was administered followed by further analgesia every 12-hours after surgery as needed. Following preparation of 
the surgical site, the FDL was surgically transected in the transverse plane at the myotendinous junction in the 
calf to protect the repair site from high strains. The skin was closed with a single 5-0 suture. A 1-2 cm incision was 
then made on the posterior surface of the hindpaw, soft tissue was retracted to identify the FDL, and the FDL was 
completely transected using micro-scissors. Following transection the FDL was repaired using 8-0 nylon sutures 
(Ethicon, Somerville, NJ) in a modified Kessler pattern. The skin was closed with 5-0 suture. The animals were 
allowed unrestricted weight-bearing and movement, and had ad-libitum access to food and water.
RNA extraction and qPCR. Total RNA was extracted from healing tendons between 3–28 days 
post-surgery. RNA was extracted from the repair site and 1-2 mm of native tendon on both sides of the repair. 
RNA was extracted from 3 repairs per genotype per time-point. RNA was extracted using TRIzol reagent 
(Life Technologies). 500ng of RNA was used for reverse transcription of cDNA using iScript cDNA synthesis 
kit (Bio-Rad, Hercules, CA). Quantitative PCR (qPCR) was then run using cDNA and gene specific primers 
(Supplemental Table 1). Expression was normalized to expression in day 3 WT repairs, and the internal con-
trol β-actin. Expression was normalized to day 3 repairs because the expression levels of most genes of inter-
est are extremely low, or un-detectable in un-operated mice, likely due to the quiescent nature of these cells. 
Normalization to day 3 allows a more direct comparison of changes in gene expression changes during the healing 
process. All qPCR was run in triplicate and repeated at least twice.
Histology- Frozen Sectioning. Following sacrifice the hind limbs of S100a4-Cre+; ROSAnT/nG and Scx-Cre; 
ROSAnT/nG mice were removed at the mid-tibia, and skin and excess soft tissue was removed. The skin on the sole 
of the foot remained intact so as not to disturb the repair site. Tissues were fixed in 10% neutral buffered formalin 
for 24 hrs at 4 °C, decalcified in 14% EDTA (pH 7.2-7.4) for 4 days at 4 °C, and processed in 30% sucrose (in PBS) 
for 24 hours prior to embedding in Cryomatrix (ThermoFisher, Waltham, MA). Eight-micron serial sagittal sec-
tions were cut using a cryotape-transfer method46. Sections were affixed to glass slides using 1% chitosan in 0.25% 
acetic acid, dried overnight at 4 °C, and coverslipped using Fluoromount aqueous mounting medium (F46802, 
Sigma, St. Louis, MO. Following fluorescent imaging, coverslips were gently removed in PBS, and slides were 
stained with Hematoxylin & Eosin, followed by dehydration and coverslipping. Both fluorescent and brightfield 
imaging was done on a VS120 Virtual Slide Microscope (Olympus, Waltham, MA). Images are representative of 
at least three specimens per time-point.
Histology- Paraffin sectioning. Hind limbs were removed as above and fixed for 72hrs in 10% NBF 
at room temperature. Specimens were then decalcified for 14 days in 14% EDTA (pH 7.2–7.4), processed and 
embedded in paraffin. Three-micron serial sagittal sections were cut, de-waxed, rehydrated, and probed with 
antibodies for EP4 (1:100, #sc-16022, Santa Cruz Biotechnology, Dallas, TX) and α-SMA-Cy3 (1:200, #C6198, 
Sigma, St. Louis, MO) overnight at 4 °C. An AlexaFlour 488 secondary antibody was used with EP4 (1:200, #705-
546-147, Jackson ImmunoResearch, West Grove, PA). The nuclear counterstain DAPI was used, and fluorescence 
was imaged with a VS120 Virtual Slide Microscope (Olympus, Waltham, MA). Following imaging, coverslips 
were removed by immersing slides in PBS, and then slides were stained with Hematoxylin & Eosin (H&E).
Quantification of fluorescence. Digital fluorescent images obtained from the slide scanner were pro-
cessed using Visiopharm image analysis software v.6.7.0.2590 (Visiopharm, Hørsholm, Denmark) Automatic 
segmentation was done using the threshold classifier to define cell populations based on fluorescent channel. A 
double constraint was defined to determine co-localization of EP4 and α-SMA staining. Regions of interest were 
drawn to include only the scar tissue area for processing. To improve accuracy of quantification, manual correc-
tion was done to exclude sutures/blood vessels, and a post-processing step was added to ignore any debris smaller 
than 10 µm2. The area of each fluorescent signal was calculated, and these values were used to determine overall 
percentage of each cell type or stain present in the scar tissue.
Assessment of Gliding Function. Following sacrifice the hindlimb was removed at the knee, and skin 
was removed down to the ankle. The FDL was isolated proximally near the original myotendinous junction 
and secured using cyanoacrylate between two pieces of tape as previously described39, 47. Briefly, the tibia was 
secured in an alligator clip and the tendon was incrementally loaded with small weights from 0–19 g; digital 
images were taken at each load. The flexion angle of the metatarsophalangeal (MTP) joint was measured from the 
digital images. The MTP Flexion angle corresponds to the degrees of flexion upon application of the 19 g weight. 
Un-injured tendons undergo complete flexion of the digits at 19 g. Gliding resistance was based on the changes 
in MTP flexion angle of the range of applied loads with higher gliding resistance indicative of impaired gliding 
function and adhesion formation. Eight-10 specimens per genotype per time-point were analyzed for gliding 
function.
Biomechanical testing. Following Gliding testing, the tibia was removed at the ankle and the toes and 
proximal section of the FDL in the tape were secured in opposing ends of a custom grips39, 47 on an Instron 
8841 DynaMightTM axial servohydraulic testing system (Instron Corporation, Norwood, MA). The tendons were 
tested in tension at a rate of 30mm/minute until failure. Maximum load at failure was automatically logged, while 
stiffness was calculated at the slope of the linear region of the force-displacement curve. Eight-10 specimens per 
genotype per time-point underwent mechanical testing. Biomechanical testing was not conducted on earlier 
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time-points due to the fragility of the samples and because our previous studies39 have demonstrated that the 
observed max load at failure at early time-points is entirely due to the sutures and not the healing tissue.
Statistical analyses. Quantitative data are presented at mean ± standard error of the mean (SEM). A 
two-way analysis of variance (ANOVA) with Bonferroni’s multiple comparisons test was used to analyze qPCR, 
biomechanical and gliding data of WT and EP4cKOS100a4 tendon repairs over time. A one-way ANOVA with 
Bonferroni’s multiple comparisons test was used to analyze nGFP+ quantification. A t-test was used to analyze 
biomechanical and gliding data from un-injured tendons, EP4cKOScx vs. WT repairs at day 14, and quantification 
of immunofluorescence.
Data Availability Statement. All data generated or analysed during this study are included in this article.
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